BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12492116)

  • 1. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
    Eid MA; Lewis RW; Kumar MV
    Mol Cancer Ther; 2002 Aug; 1(10):831-40. PubMed ID: 12492116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
    Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
    Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondria from TRAIL-resistant prostate cancer cells are capable of responding to apoptotic stimuli.
    Liang Y; Eid MA; Lewis RW; Kumar MV
    Cell Signal; 2005 Feb; 17(2):243-51. PubMed ID: 15494215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
    J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.
    Rokhlin OW; Taghiyev AF; Guseva NV; Glover RA; Syrbu SI; Cohen MB
    Cancer Biol Ther; 2002; 1(6):631-7. PubMed ID: 12642685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria.
    Thomas WD; Zhang XD; Franco AV; Nguyen T; Hersey P
    J Immunol; 2000 Nov; 165(10):5612-20. PubMed ID: 11067917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
    Kim YS; Schwabe RF; Qian T; Lemasters JJ; Brenner DA
    Hepatology; 2002 Dec; 36(6):1498-508. PubMed ID: 12447876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway.
    Wagner KW; Engels IH; Deveraux QL
    J Biol Chem; 2004 Aug; 279(33):35047-52. PubMed ID: 15173176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release.
    Gibson EM; Henson ES; Haney N; Villanueva J; Gibson SB
    Cancer Res; 2002 Jan; 62(2):488-96. PubMed ID: 11809700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP.
    Taghiyev AF; Guseva NV; Harada H; Knudson CM; Rokhlin OW; Cohen MB
    Mol Cancer Res; 2003 May; 1(7):500-7. PubMed ID: 12754297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis is dependent on activation of cysteine and serine proteases.
    Park IC; Park MJ; Woo SH; Lee KH; Lee SH; Rhee CH; Hong SI
    Cytokine; 2001 Aug; 15(3):166-70. PubMed ID: 11554786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
    Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells.
    Sarker M; Ruiz-Ruiz C; Robledo G; López-Rivas A
    Oncogene; 2002 Jun; 21(27):4323-7. PubMed ID: 12082620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.